Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding.
Aged
Aged, 80 and over
Amyloid Neuropathies, Familial
/ complications
Atrial Fibrillation
/ drug therapy
Factor Xa Inhibitors
/ administration & dosage
Female
Hemorrhage
/ blood
Humans
Ischemic Attack, Transient
/ blood
Male
Middle Aged
Stroke
/ drug therapy
Thrombosis
/ drug therapy
Warfarin
/ administration & dosage
anticoagulation
atrial fibrillation
cardiac amyloidosis
stroke
transthyretin
Journal
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
ISSN: 1744-2818
Titre abrégé: Amyloid
Pays: England
ID NLM: 9433802
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
21
8
2020
medline:
16
11
2021
entrez:
21
8
2020
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown. To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs). This study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death. Of 290 patients, 217 patients (74.8%) had AF. Of those with AF ( Patient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown.
OBJECTIVES
OBJECTIVE
To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs).
METHODS
METHODS
This study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death.
RESULTS
RESULTS
Of 290 patients, 217 patients (74.8%) had AF. Of those with AF (
CONCLUSION
CONCLUSIONS
Patient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.
Identifiants
pubmed: 32814468
doi: 10.1080/13506129.2020.1810010
pmc: PMC8018530
mid: NIHMS1675543
doi:
Substances chimiques
Factor Xa Inhibitors
0
Warfarin
5Q7ZVV76EI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-34Subventions
Organisme : NIA NIH HHS
ID : K24 AG036778
Pays : United States
Références
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Am J Cardiol. 2005 Feb 15;95(4):535-7
pubmed: 15695149
Circulation. 2005 Sep 27;112(13):2047-60
pubmed: 16186440
Circulation. 2009 May 12;119(18):2490-7
pubmed: 19414641
Curr Cardiol Rep. 2018 Sep 12;20(11):106
pubmed: 30209626
J Cardiovasc Electrophysiol. 2016 Feb;27(2):242-52
pubmed: 26519209
J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891
pubmed: 31171094
J Am Heart Assoc. 2013 Feb 01;2(1):e005694
pubmed: 23525446
Amyloid. 2015;22(3):147-55
pubmed: 25997105
Circulation. 2002 Oct 15;106(16):2091-7
pubmed: 12379579
BMJ Open. 2019 Mar 30;9(3):e022478
pubmed: 30928922
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
JAMA. 2002 Nov 20;288(19):2441-8
pubmed: 12435257
J Thorac Dis. 2018 Mar;10(3):2034-2045
pubmed: 29707360
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
Arch Intern Med. 2012 Apr 23;172(8):623-31; discussion 631-3
pubmed: 22450212
Stroke. 2012 Dec;43(12):3298-304
pubmed: 23150654
ESC Heart Fail. 2018 Oct;5(5):772-779
pubmed: 29916559
Circulation. 2017 Apr 4;135(14):1357-1377
pubmed: 28373528
Circulation. 2007 Nov 20;116(21):2420-6
pubmed: 17984380
Circulation. 2012 Nov 13;126(20):2381-91
pubmed: 23071159
Am J Med. 1977 May;62(5):677-86
pubmed: 871125
Ann Intern Med. 2012 Dec 4;157(11):796-807
pubmed: 22928173
J Am Coll Cardiol. 2016 Jul 12;68(2):161-72
pubmed: 27386769
J Am Heart Assoc. 2017 Feb 14;6(2):
pubmed: 28196815